Buy & Sell Soleno Therapeutics Inc (SLNO) – Soleno Therapeutics Inc Price Today
Key Stats
- $2.76BMarket Cap
- HealthSector
- -5.68%3M Drawdown
- $2.56BEnterprise Value
- -Dividend Yield
- 24 daysTypical Hold Time
Soleno Therapeutics Inc (SLNO) is currently valued at a market capitalization of $2.76B, with an enterprise value of $2.56B. Over the past 52 weeks, Soleno Therapeutics Inc has traded between a low of $30.05 and a high of $88.49, highlighting its annual price range. Over the past three months, Soleno Therapeutics Inc has recorded a drawdown of -5.68%, reflecting recent price volatility. On average, investors hold Soleno Therapeutics Inc for approximately 24 days, indicating typical investor behavior on the platform.
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases. The company's lead product candidate, DCCR (Diazoxide Choline Extended-Release), is currently in late-stage clinical trials for the treatment of Prader-Willi Syndrome (PWS), a complex genetic disorder that causes a constant feeling of hunger (hyperphagia). Soleno is committed to addressing the significant unmet medical need in the PWS community.
Most Recent News
UBS advisor investigated for allegedly recommending unapproved 99 Acquisition Group investments
Meyer Wilson Werning, an investor protection law firm, is investigating UBS advisor Daniel Merithew Allen for allegedly recommending unapproved investments in 99 Acquisition Group LLC to clients. This practice, known as "selling away," violates FINRA...

AI-driven visibility shifts digital marketing from campaigns to integrated infrastructure systems.
NEWMEDIA.COM highlights a major shift in digital marketing where AI Visibility Infrastructure integrates search, authority, content, and analytics to ensure brands are discoverable and recommended by AI systems. Traditional search rankings are becomi...

Oruka Therapeutics insider sold 105,000 shares worth $6.2M, signaling possible shifts ahead.
An insider at Oruka Therapeutics sold 105,000 shares valued at $6.2 million. Such a large sale by someone within the company could indicate changes in confidence or strategy. Investors should watch for further developments or official statements from...
